Original Publication Date: >5 May, 2017
Publication / Source: Future Neurology
Authors: Burchell JT, Panegyres PK
In 2015, we published a review on novel cerebrospinal fluid (CSF) biomarkers for detecting Alzheimer’s disease (AD) . We summarized the main potential CSF biomarkers as low amyloid β1–42 (Aβ1–42) and a high total tau (T-tau) and phosphorylated tau (p-tau). We discussed a number of other potential biomarkers, including those involving blood–brain barrier integrity (PDGFR-β), mitochondrial DNA (mtDNA), VEGF family members, calcium-sensor protein VILIP-1, β-site APP-cleaving enzyme 1 and the astrocyte marker YKL-40. More recently, a number of studies have focused on the potential use of other biomarkers such as TGF-β, neurofilament light polypeptide (NFL), autotaxin, α-syn and complement. These modules offer promise for earlier detection of AD and other neurodegenerative disorders including Parkinson’s disease (PD) and mild cognitive impairment (MCI).